Market Overview

AbbVie: Q3 Earnings Insights



Shares of AbbVie (NYSE:ABBV) moved higher by 0.3% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 21.46% year over year to $2.83, which beat the estimate of $2.76.

Revenue of $12,902,000,000 up by 52.16% year over year, which beat the estimate of $12,720,000,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $10.47 and $10.49.

How To Listen To The Conference Call

Date: Oct 30, 2020

Time: 09:00 AM

ET Webcast URL:

Price Action

52-week high: $101.28

Company's 52-week low was at $62.55

Price action over last quarter: down 15.70%

Company Description

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013. The recent announced acquisition of Allergan will add several new drugs in aesthetics and women's health.


Related Articles (ABBV)

View Comments and Join the Discussion!

Posted-In: Earnings News